Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02444793 · ClinicalTrials.gov registry record · Phase 1
A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02444793 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 24 participants.
The verdict
NCT02444793, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study is a Phase 1b, open label, multi center, multi-dose trial designed to estimate the maximum tolerated dose (MTD) and select the recommended dose for phase 2 (RP2D) investigations of PF- 05082566 in combination with KW-0761 (mogamulizumab) in patients with advanced solid tumors. Once the MTD of PF-05082566 administered in combination with KW-0761 is estimated (dose finding), one or more expansion cohorts of patients with selected advanced solid tumors (dose-expansion ) will be enrolled to further characterize the combination in term of safety profile, anti tumor activity, pharmacokinetics, pharmacodynamics and biomarkers modulation.
Interventions
- DRUG PF-05082566
- DRUG KW-0761
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2015-05 |
| Est. Completion | 2017-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02444793
The ClinicalTrials.gov registry entry for NCT02444793 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PF-05082566 is the first listed.
NCT02444793 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02444793 about?
NCT02444793 is a clinical study titled "A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors". This study is a Phase 1b, open label, multi center, multi-dose trial designed to estimate the maximum tolerated dose (MTD) and select the recommended dose for phase 2 (RP2D) investigations of PF- 05082566 in combination with KW-0761 (mogamulizumab) in patients with advanced solid tumors. Once the MT...
What is the current status of trial NCT02444793?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2015-05. Estimated completion is 2017-10.
What interventions are being tested in trial NCT02444793?
The interventions under investigation include: PF-05082566 (DRUG), KW-0761 (DRUG).
Who is sponsoring clinical trial NCT02444793?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.